HLUNAC Stock Overview A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
H. Lundbeck A/S Competitors Price History & Performance
Summary of share price highs, lows and changes for H. Lundbeck Historical stock prices Current Share Price DKK 34.25 52 Week High DKK 34.25 52 Week Low DKK 23.95 Beta 0 1 Month Change 0% 3 Month Change n/a 1 Year Change 9.42% 3 Year Change n/a 5 Year Change n/a Change since IPO 4.42%
Recent News & Updates
H. Lundbeck A/S Announces Positive Results from the Resolve Trial Dec 03
H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy Nov 27
H. Lundbeck A/S Raises Earnings Guidance for the Year 2024 Nov 14
H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention Nov 01 H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion. Oct 15
H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion. Oct 14
See more updates
H. Lundbeck A/S Announces Positive Results from the Resolve Trial Dec 03
H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy Nov 27
H. Lundbeck A/S Raises Earnings Guidance for the Year 2024 Nov 14
H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention Nov 01 H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion. Oct 15
H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion. Oct 14
H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease Oct 03 H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders Sep 27
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder Jun 25
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial Jun 20
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia Jun 05
H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025 May 17
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024 May 16
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024 May 14
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD Apr 10 Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia Mar 28
H. Lundbeck A/S Announces Management Appointments H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage Mar 15
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023
H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024 Feb 05 Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial Jan 31
H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024
H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024 Nov 08
H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea Sep 14 Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults Sep 08
H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart Aug 19
H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024 Aug 18
H. Lundbeck A/S Raises Earnings Guidance for the Year 2023 Aug 17 H. Lundbeck A/S Appoints Charl Van Zyl as New President
H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention Jun 16
Less than half of directors are independent Jun 01 H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease
Less than half of directors are independent Feb 23
Full year 2022 earnings released Feb 10
H. Lundbeck A/S Proposes Dividend for 2022 Feb 09
H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023 Feb 08
Less than half of directors are independent Feb 08
Less than half of directors are independent Jan 25
H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States Jan 13 Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia Jan 08
Less than half of directors are independent Dec 02 H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023 H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023
H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine) Oct 18
Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults Sep 14
Second quarter 2022 earnings released: EPS: kr.0.51 (vs kr.1.90 in 2Q 2021) Aug 18
H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022 Aug 17
Less than half of directors are independent Aug 10
H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022 Aug 10
Less than half of directors are independent Jul 20
H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole Jun 28 Shareholder Returns HLUNAC GB Pharmaceuticals GB Market 7D 0% -1.5% -1.5% 1Y 9.4% -2.8% 3.5%
See full shareholder returns
Return vs Market: HLUNAC exceeded the UK Market which returned -2.4% over the past year.
Price Volatility Is HLUNAC's price volatile compared to industry and market? HLUNAC volatility HLUNAC Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: HLUNAC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HLUNAC's volatility change over the past year.
About the Company H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products.
Show more H. Lundbeck A/S Fundamentals Summary How do H. Lundbeck's earnings and revenue compare to its market cap? HLUNAC fundamental statistics Market cap DKK 33.45b Earnings (TTM ) DKK 2.48b Revenue (TTM ) DKK 19.38b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HLUNAC income statement (TTM ) Revenue DKK 19.38b Cost of Revenue DKK 4.30b Gross Profit DKK 15.08b Other Expenses DKK 12.60b Earnings DKK 2.48b
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 08, 2023
Earnings per share (EPS) 2.50 Gross Margin 77.79% Net Profit Margin 12.79% Debt/Equity Ratio 20.9%
How did HLUNAC perform over the long term?
See historical performance and comparison Dividends
1.9% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/08/27 06:01 End of Day Share Price 2023/05/30 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources H. Lundbeck A/S is covered by 39 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Ankersen ABG Sundal Collier Kamla Singh AlphaValue Charles Pitman Barclays
Show 36 more analysts 